The creation of a dendritic cell-based vaccine marked the beginning of a new chapter in the immunological treatment of Alzheimer's disease. Dendritic cell therapy for Alzheimer's disease induces a specific immune response directed against amyloid beta, which does not trigger immune inflammation of healthy brain tissue. Due to this, the use of dendritic cell-based vaccines for Alzheimer's disease is devoid of the disadvantages of other types of immunotherapy because it does not cause ARIA, hemorrhages, or brain tissue swelling.The use of DC therapies in AD involves the manufacture of a personalized vaccine based on the patient's blood cells. Such a drug cannot simply be purchased at the pharmacy network because laboratory assistants, doctors, and technologists are working on its creation. Here are the main steps in dendritic cell therapy:The completed vaccine for Alzheimer's disease is injected subcutaneously into the area of the lymphatic collectors in the head and neck. Patients can additionally receive vitamin preparations. The treatment takes place in a day hospital and is generally well tolerated. The effect of DC therapies in AD persists even after the natural destruction of the vaccine in the body due to the fact that the memory cells of the immune system retain information about the need to attack amyloid beta. Without a doubt, dendritic cell therapy will enter the protocols for the treatment and prevention of Alzheimer's disease after the completion of clinical trials.
Bullish
Market Data 
Markets 
